 There is a lot hinging on whether weight loss drugs like Eli Lilly's Zepbound, the sister drug to its diabetes drug Manjaro, will be able to help with sleep apnea. The Wall Street Journal says studies running right now in Australia to see if the weight loss from taking Zepbound will help could mean more health insurers might finally start covering the drugs. That would allow millions more people to take them and open the door to billions in further sales.